| abstract |
1. The compound having the formula I! ! or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or tautomer thereof, where! W represents a single bond, - (CH2) m-, -O-, -S (O) n-, -NR7-, -C (O) -, -C (O) O-, -C (O) NR7 -, -NR7C (O) NR7- or -NR7C (O) O-; ! R1 is —CO2R9-C (O) NR8aR8b, nitrile or tetrazolyl; ! R2 represents (a) hydrogen; (b) halogen; (c) (C1-C6) alkyl; (d) (C1-C6) alkyl substituted with aryl, hydroxy, carboxy, alkoxy, carbamoyl, (C1-C6) alkylcarbamoyl, di ((C1-C6) alkyl) carbamoyl, (C3-C7) cycloalkylcarbamoyl or (C3-C7 ) heterocyclylcarbamoyl; (e) (C1-C6) alkyl mono-, di- or trisubstituted with halogen; (f) (C3-C7) cycloalkyl; (g) -NR8aR8b; (h) -SR3 or (i) (C1-C6) alkoxy, optionally mono-, di- or trisubstituted with halogen; ! each R3 independently represents (a) hydrogen; (b) (C1-C6) alkyl optionally mono-, di- or trisubstituted with halogen; (c) (C3-C7) cycloalkyl or (d) -C (O) R9; ! R4a and R4b are each independently selected from hydrogen or (C1-C6) alkyl; ! each R5 independently represents (a) hydrogen; (b) halogen; (c) cyano; (d) nitro; (e) hydroxy; (f) phenyl; (g) phenyloxy; (h) benzyl; (i) benzyloxy; (j) guanidino; (k) heterocyclyl; (l) -NR8aR8b; (m) sulfamoyl; (n) (C1-C6) alkylsulfonyl; (o) (C1-C6) alkylaminosulfonyl; (p) di (C1-C6) alkylaminosulfonyl; (q) -C (O) R9; (r) -C (O) OR9; (s) -C (O) NR8aR8b; (t) -OC (O) NR8aR8b; (u) -NR7C (O) OR9; (v) -NR7C (O) R9; (w) (C2-C6) alkenyl; (x) (C1-C6) alkyl optionally mono-, di- or trisubstituted with halogen; (y) (C1-C6) alkoxy, optionally mono-, di- or trisubstituted with halogen; or (z) (C1-C6) alkylthio, optionally mono-, di- or trisubstituted with halogen; ! R6 represents (a) hydrogen; (b) (C1-C6) alkyl; (c) (C2-C6) alkenyl; (d) (C2-C6) alkynyl; (e) (C3-C7) cycloalkyl; (f) (C1-C6) alkyl substituted with aryl or heteroaryl; (g) (C2-C4) alkenyl substituted with aryl or heteroaryl; (h) (C1-C6) alkyl, mono, di |